ライフサイエンスコーパス: portopulmonary hypertension

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 es in diagnosis, treatment and management of portopulmonary hypertension.

2 liver disease was not related to the risk of portopulmonary hypertension.

3 therefore be integral to the development of portopulmonary hypertension.

4 confidence interval 0.09-0.65, P = 0.005) of portopulmonary hypertension.

5 d aerosolized epoprostenol in a patient with portopulmonary hypertension.

6 We studied 15 consecutive patients with portopulmonary hypertension; 14 underwent acute administ

7 Portopulmonary hypertension affects up to 6% of patients

8 Advances in diagnosis and therapy of portopulmonary hypertension allow patients with cirrhosi

9 Hepatopulmonary syndrome and portopulmonary hypertension are two pulmonary vascular c

10 atients were receiving ongoing treatment for portopulmonary hypertension at the time of transplant.

11 rtal hypertension (hepatopulmonary syndrome, portopulmonary hypertension, cardiac dysfunction), and h

12 Portopulmonary hypertension, defined as mean pulmonary a

13 increased pulmonary vascular resistance from portopulmonary hypertension, has been associated with in

14 New treatment modalities of severe portopulmonary hypertension have been introduced, and ma

15 t to determine the clinical risk factors for portopulmonary hypertension in patients with advanced li

16 In moderate to severe portopulmonary hypertension, intravenous epoprostenol re

17 ng of portal hypertension is referred to as "portopulmonary hypertension." Intravenous epoprostenol (

18 Portopulmonary hypertension is a known complication in t

19 criteria; II. Hepatopulmonary syndrome; III. Portopulmonary hypertension; IV. Implications for liver

20 Portopulmonary hypertension may be screened with transth

21 c shunts in patients with moderate or severe portopulmonary hypertension (POPH) and determined the as

22 Portopulmonary hypertension (PoPH) is diagnosed in 2-6%

23 Portopulmonary hypertension (POPH) is the elevation of p

24 isorders, hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) may occur as a conseq

25 clinical research: hepatopulmonary syndrome, portopulmonary hypertension (POPH), and hepatic hydrotho

26 aracterized: hepatopulmonary syndrome (HPS), portopulmonary hypertension (POPH), and hepatic hydrotho

27 ase (MELD) exception points to patients with portopulmonary hypertension (POPH), but potentially impo

28 of the liver transplant (OLT) candidate with portopulmonary hypertension (PPHTN) has dramatically cha

29 ension with portal hypertension, also called portopulmonary hypertension (PPHTN), is a known complica

30 g/min, for a 4-month period, after which the portopulmonary hypertension resolved and the patient und

31 and now report the first patient with severe portopulmonary hypertension successfully treated with ep

32 ale sex was associated with a higher risk of portopulmonary hypertension than male sex (adjusted odds

33 A patient with severe portopulmonary hypertension was treated with intravenous

34 cular disease, congenital heart disease, and portopulmonary hypertension were analyzed with other pat

35 high risk of death in those with significant portopulmonary hypertension, where targeted medical ther

36 is were associated with an increased risk of portopulmonary hypertension, whereas hepatitis C infecti

37 irectly linked estrogen to increased risk of portopulmonary hypertension, whereas others implicate in

38 ecently reported the successful treatment of portopulmonary hypertension with chronic intravenous epo

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。